Commentary on OPTIMIZE-2: Duration of zoledronic acid for breast cancer bone metastases

Initial recruitment to OPTIMIZE-2 was slow due to placebo as a comparator arm. The study was then redesigned to address duration of treatment. Robert Coleman explains how the results can help plan treatment, highlighting advantages of a less intensified approach.

The findings can't be applied to other treatments for bone metastases and there is no need for further trials on bisphosphonate duration.

Watch the video here